• Citer

Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

par André, Marie Josèphe;Baudoux, Etienne;Bron, Dominique ;Canon, Jean-Luc;D'Hondt, Veronique ;Fassotte, Marie-France;D'Hondt, Lionel;Fillet, Georges;Humblet, Yves;Jerusalem, Guy;Vermeulen, Philippe;Symann, Michel;Beguin, Yves
Référence Transfusion, 43, 1, page (50-57)
Publication Publié, 2003-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies
Auteur:	André, Marie Josèphe; Baudoux, Etienne; Bron, Dominique; Canon, Jean-Luc; D'Hondt, Veronique; Fassotte, Marie-France; D'Hondt, Lionel; Fillet, Georges; Humblet, Yves; Jerusalem, Guy; Vermeulen, Philippe; Symann, Michel; Beguin, Yves
Informations sur la publication:	Transfusion, 43, 1, page (50-57)
Statut de publication:	Publié, 2003-01
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- therapy
	Female
	Filgrastim -- pharmacology
	Hematopoietic Stem Cell Mobilization
	Hematopoietic Stem Cell Transplantation -- adverse effects
	Humans
	Leukapheresis
	Lymphoma -- therapy
	Male
	Middle Aged
	Multiple Myeloma -- therapy
	Transplantation, Autologous
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	FLWIN
Langue:	Anglais
Identificateurs:	urn:issn:0041-1132
	info:doi/10.1046/j.1537-2995.2003.00273.x
	info:pii/trf273
	info:pmid/12519430